An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Ilixadencel (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- Acronyms MERECA
- Sponsors Immunicum
- 03 Apr 2018 According to an Immunicum media release, the 18-month follow-up period for the last patient treated will be completed in mid-year 2019.
- 27 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Aug 2019.
- 27 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019.